Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Kristiansen, Paul A ^a   Ba, Absatou K ^b   Sanou, Idrissa ^c,d   Ouédraogo, Abdoul Salam ^c   Ouédraogo, Rasmata ^e   Sangaré, Lassana ^d   Diomandé, Fabien ^f,g   Kandolo, Denis ^f   Thomas, Jennifer D ^g   Clark, Thomas A ^g   LaForce, Marc ^h   Caugant, Dominique A ^a,i  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b Laboratoire National de Sante Publique   (Burkina Faso)

^c Centre Hospitalier Universitaire Souro Sanou   (Burkina Faso)

^d Centre Hospitalier Universitaire Yalgado   (Burkina Faso)

^e Centre Hospitalier Universitaire Pediatrique Charles de Gaulle   (Burkina Faso)

^f World Health Organization Ouagadougou   (Burkina Faso)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^h Meningitis Vaccine Project   (France)

ⁱ UNIVERSITY OF OSLO   (Norway)

Author keywords

Burkina Faso; Carriage; Conjugate vaccine; Meningitis; Meningitis belt; MLST; Neisseria meningitidis

Indexed keywords

CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; MENINGOCOCCUS VACCINE; PENICILLIN G; RIFAMPICIN; SULFONAMIDE; TETRACYCLINE;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BURKINA FASO; CEREBROSPINAL FLUID; CHILD; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; EPIDEMIC; GENOTYPE; HUMAN; MASS IMMUNIZATION; MENINGITIS; MENINGOCOCCOSIS; MINIMUM INHIBITORY CONCENTRATION; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS; NONHUMAN; OROPHARYNX; PHENOTYPE; PRESCHOOL CHILD; PREVALENCE; SCHOOL CHILD;

EID: 84880934608     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-363     Document Type: Article

References (49)

1. Lapeyssonnie L. La méningite cérébrospinale en Afrique [in French]. Bull World Health Organ 1963, 28(Suppl):3-114.
2. Molesworth AM, Thomson MC, Connor SJ, Cresswell MP, Morse AP, Shears P, et al. Where is the Meningitis Belt? Defining an area at risk of epidemic meningitis in Africa. Trans R Soc Trop Med Hyg 2002, 96:242-249. 10.1016/S0035-9203(02)90089-1, 12174770.
3. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl):B51-B63.
4. Nicolas P, Norheim G, Garnotel E, Djibo S, Caugant DA. Molecular epidemiology of Neisseria meningitidis isolated in the African meningitis belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol 2005, 43:5129-5135. 10.1128/JCM.43.10.5129-5135.2005, 1248450, 16207974.
5. Caugant DA, Kristiansen PA, Wang X, Mayer LW, Taha MK, Ouédraogo R, et al. Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine. PLoS One 2012, 7:e46019. 10.1371/journal.pone.0046019, 3459830, 23029368.
6. Nicolas P, Decousset L, Riglet V, Castelli P, Stor R, Blanchet G. Clonal expansion of sequence type (ST-)5 and emergence of ST-7 in serogroup A meningococci, Africa. Emerg Infect Dis 2001, 7:849-854. 2631866, 11747698.
7. Nicolas P, Ait MN, Al-Awaidy S, Al BS, Sulaiman N, Issa M, et al. Pharyngeal carriage of serogroup W135 Neisseria meningitidis in Hajjees and their family contacts in Morocco, Oman and Sudan. APMIS 2005, 113:182-186. 10.1111/j.1600-0463.2005.apm1130305.x, 15799761.
8. Koumaré B, Ouedraogo-Traoré R, Sanou I, Yada AA, Sow I, Lusamba PS, et al. The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine 2007, 25(suppl):A37-A41.
9. Nathan N, Rose AM, Legros D, Tiendrebeogo SR, Bachy C, Bjorlow E, et al. Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis 2007, 13:920-923. 10.3201/eid1306.060940, 2792856, 17553237.
10. Mayer LW, Reeves MW, Al-Hamdan N, Sacchi CT, Taha MK, Ajello GW, et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J Infect Dis 2002, 185:1596-1605. 10.1086/340414, 12023765.
11. Boisier P, Nicolas P, Djibo S, Taha M-K, Jeanne I, Mainassara HB, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007, 44:657-663. 10.1086/511646, 17278055.
12. Nicolas P, Djibo S, Sidikou F, Tenebray B, Stor R, Boisier P, et al. Epidemics caused by group X meningoccal meningitis in Africa in 2006. Med Trop (Mars) 2006, 66:494.
13. Delrieu I, Yaro S, Tamekloe TAS, Njanpop-Lafourcade B-M, Tall H, Jaillard P, et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One 2011, 6:e19513. 10.1371/journal.pone.0019513, 3098835, 21625480.
14. World Health Organization Control of epidemic meningococcal disease. WHO practical guidelines 1998, WHO/EMC/BAC/98 3 1998, 2, Available at: http://www.searo.who.int/entity/emergencies/documents/who-meningitis-guidelines.pdf. Accessed 31 July 2013., World Health Organization.
15. World Health Organization International Coordinating Group on VaccineProvision for Epidemic Meningitis Control (ICG). Guidelines for applying to the emergency stockpile. WHO Offset Publ 2008, Available at: https://extranet.who.int/aim_elearning/en/vaccines/mening/pdf/ICG_guidelines_2008_02_09.pdf. Accessed 31 July 2013., World Health Organization.
16. Dellicour S, Greenwood B. Systematic review: Impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop Med Int Health 2007, 12:1409-1421. 10.1111/j.1365-3156.2007.01929.x, 17961128.
17. LaForce FM, Okwo-Bele J-M. Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood) 2011, 30:1049-1057.
18. Frasch CE, Preziosi MP, LaForce FM. Development of a group A meningococcal conjugate vaccine, MenAfriVac. Hum Vaccin Immunother 2012, 8:715-724. 10.4161/hv.19619, 22495119.
19. Hirve SS, Bavdekar AN, Pandit AN, Juvekar SK, Patil M, Preziosi MP, et al. Safety and immunogenicity of a new meningococcal A conjugate vaccine in healthy Indian children aged 2-10 years. 16th International Pathogenic Neisseria Conference 2008, P227:285-286.
20. Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011, 364:2293-2304. 10.1056/NEJMoa1003812, 21675889.
21. Djingarey MH, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R, Kandolo D, et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine 2012, 30(Suppl):B40-B45.
22. Kristiansen PA, Diomandé F, Absatou KB, Sanou I, Ouédraogo AS, Ouédraogo R, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013, 56:354-363. 10.1093/cid/cis892, 23087396.
23. Novak RT, Kambou JL, Diomande FV, Tarbangdo TF, Ouedraogo-Traore R, Sangare L, et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 2012, 12:757-764. 10.1016/S1473-3099(12)70168-8, 22818241.
24. Musher DM. Pneumococcal vaccine - direct and indirect (herd) effects. N Engl J Med 2006, 354:1522-1524. 10.1056/NEJMe068038, 16598050.
25. Tsang R. Capsule switching and capsule replacement in vaccine-preventable bacterial diseases. Lancet Infect Dis 2007, 7:569-570. 10.1016/S1473-3099(07)70191-3, 17714669.
26. Trotter CL, Ramsay ME, Gray S, Fox A, Kaczmarski E. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis 2006, 6:616-617. 10.1016/S1473-3099(06)70584-9, 17008169.
27. Long SS. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine. Clin Infect Dis 2005, 41:30-34. 10.1086/430608, 15937759.
28. Alcalá B, Arreaza L, Salcedo C, Uría MJ, De La Fuente LD, Vázquez JA. Capsule switching among C:2b:P1.2,5 meningococcal epidemic strains after mass immunization campaign, Spain. Emerg Infect Dis 2002, 8:1512-1514. 10.3201/eid0812.020081, 2738524, 12498676.
29. Lancellotti M, Guiyoule A, Ruckly C, Hong E, Alonso JM, Taha MK. Conserved virulence of C to B capsule switched Neisseria meningitidis clinical isolates belonging to ET-37/ST-11 clonal complex. Microbes Infect 2006, 8:191-196. 10.1016/j.micinf.2005.06.012, 16182586.
30. Simoes MJ, Cunha M, Almeida F, Furtado C, Brum L. Molecular surveillance of Neisseria meningitidis capsular switching in Portugal, 2002-2006. Epidemiol Infect 2009, 137:161-165. 10.1017/S0950268808001106, 18667108.
31. Wang Q, Shao Z, Wang X, Gao Y, Li M, Xu L, et al. Genetic study of capsular switching between Neisseria meningitidis sequence type 7 serogroup A and C strains. Infect Immun 2010, 78:3883-3888. 10.1128/IAI.00363-10, 2937455, 20624905.
32. Harrison LH, Shutt KA, Schmink SE, Marsh JW, Harcourt BH, Wang X, et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era - United States, 2000-2005. J Infect Dis 2010, 201:1208-1224. 10.1086/651505, 2838939, 20199241.
33. Snape M, Pollard A. No evidence for capsule replacement...and Wales - authors' reply. Lancet Infect Dis 2006, 6:617-618.
34. Kristiansen PA, Diomande F, Wei SC, Ouedraogo R, Sangare L, Sanou I, et al. Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine. Clin Vaccine Immunol 2011, 18:435-443. 10.1128/CVI.00479-10, 3067389, 21228139.
35. Ajello GW, Feeley JC, Hayes PS. Trans-isolate medium: a new medium for primary culturing and transport of Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. J Clin Microbiol 1984, 1984:20.
36. Taha M-K. Simultaneous approach for nonculture PCR-based identification and serogroup prediction of Neisseria meningitidis. J Clin Microbiol 2000, 38:855-857. 86222, 10655397.
37. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 1998, 95:3140-3145. 10.1073/pnas.95.6.3140, 19708, 9501229.
38. Russell JE, Jolley KA, Feavers IM, Maiden MCJ, Suker J. PorA variable regions of Neisseria meningitidis. Emerg Infect Dis 2004, 10:674-678. 10.3201/eid1004.030247, 3323080, 15200858.
39. Thompson EAL, Feavers IM, Maiden MCJ. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 2003, 149:1849-1858. 10.1099/mic.0.26131-0, 12855736.
40. Caugant DA, Hoiby EA, Froholm LO, Brandtzaeg P. Polymerase chain reaction for case ascertainment of meningococcal meningitis: application to the cerebrospinal fluids collected in the course of the Norwegian meningococcal serogroup B protection trial. Scand J Infect Dis 1996, 28:149-153. 10.3109/00365549609049066, 8792481.
41. WHO Inter country Support Team - WestAfrica WHO Meningitis Weekly Bulletin 2013, Available at: http://www.who.int/csr/disease/meningococcal/epidemiological/en. Accessed 20 June 2013, WHO Inter country Support Team - WestAfrica.
42. Djingarey M, Kandolo D, Lingani C, Diomandé F, Medah I, Kambou JL, et al. Evaluation of meningitis surveillance before introduction of serogroup A meningococcal conjugate vaccine - Burkina Faso and Mali. Wkly Epidemiol Rec 2012, 61:1025-1028.
43. Caugant DA, Fogg C, Bajunirwe F, Piola P, Twesigye R, Mutebi F, et al. Pharyngeal carriage of Neisseria meningitidis in 2-19-year-old individuals in Uganda. Trans R Soc Trop Med Hyg 2006, 100:1159-1163. 10.1016/j.trstmh.2006.01.004, 16765397.
44. Mueller JE, Sangare L, Njanpop-Lafourcade BM, Tarnagda Z, Traore Y, Yaro S, et al. Molecular characteristics and epidemiology of meningococcal carriage, Burkina Faso, 2003. Emerg Infect Dis 2007, 13:847-854. 10.3201/eid1306.061395, 2792846, 17553222.
45. Nicolas P, Djibo S, Tenebray B, Castelli P, Stor R, Hamidou AA, et al. Populations of pharyngeal meningococci in Niger. Vaccine 2007, 25(suppl):A53-A57.
46. Caugant DA, Tzanakaki G, Kriz P. Lessons from meningococcal carriage studies. FEMS Microbiol Rev 2007, 31:52-63. 10.1111/j.1574-6976.2006.00052.x, 17233635.
47. Guindo I, Coulibaly A, Dao S, Traoré S, Diarra S, Bougoudogo F. Clones des souches de Neisseria meningitidis au Mali (in French). Med Mal Infect 2011, 41:7-13. 10.1016/j.medmal.2010.07.001, 22133739.
48. Leimkugel J, Hodgson A, Forgor AA, Pfluger V, Dangy JP, Smith T, et al. Clonal waves of Neisseria colonisation and disease in the African meningitis belt: eight- year longitudinal study in northern Ghana. PLoS Med 2007, 4:e101. 10.1371/journal.pmed.0040101, 1831736, 17388665.
49. Beddek AJ, Li MS, Kroll JS, Jordan TW, Martin DR. Evidence for capsule switching between carried and disease-causing Neisseria meningitidis strains. Infect Immun 2009, 77:2989-2994. 10.1128/IAI.00181-09, 2708544, 19451248.